about
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquinePharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosingDiclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteersSafety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronidePharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysisHighly sensitive gas chromatographic-tandem mass spectrometric method for the determination of morphine and codeine in serum and urine in the femtomolar rangeIn vitro interaction of codeine and diclofenac.Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine.The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomesDouble-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosingThe urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans.Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.Chronopharmacology of intravenous and oral modified release verapamil.Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazoleClarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trialsPharmacogenomics of the triazole antifungal agent voriconazole.Pharmacological treatment of constipation in palliative care.Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay.Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.Clementine juice has the potential for drug interactions - In vitro comparison with grapefruit and mandarin juice.CYP3A activity: towards dose adaptation to the individual.The CYTONOX trial.
P50
Q21033481-A473DCD4-2F31-40A0-9C17-2CBD6E9FDABCQ24564973-1DBE4FAB-3DC2-42FE-A913-F91183E8CEAFQ24805872-5C1D9538-7053-4C22-9DFA-0029A12819E7Q24815501-D157A40A-4366-45A0-B178-EEB3FE24D074Q26995115-EBA16732-74D4-4D41-8FD4-0832A60E0452Q28328276-34DEB42C-A3E7-43EE-8183-D1B7B8FA5BFFQ28343852-C8774FEB-B6C7-41E9-AF2C-BB42D94762EBQ28377496-565E12C9-AE4A-4BCE-81B8-1A60BA65F98CQ31440447-65ADE48A-A2D0-441D-9AFC-AB8C7CD3AE7DQ33520508-3781B610-ADC1-4D31-9320-5A383CC1E7F2Q33608028-140C126E-223E-4470-8105-6E140FFF8631Q33764989-FA52C08F-4B19-4F35-9033-94F9BDD414D5Q33876525-F992E94C-DBE4-4C56-BFCA-3F731F894D96Q34151189-E524299D-137D-49D1-956B-5713B97D80F4Q34255693-D5F79661-F2E2-400C-B8BB-22D3C8C6C62AQ34346292-2DF49490-26E2-4B34-9A91-7A5E2D3BD8D9Q34385537-C76E9EF0-3DB7-44DF-BE8C-2263DF43115BQ34400605-CBC091A9-C432-47E7-B573-60DE1DBD125DQ34457463-1B5C666E-B77F-4B76-98D3-C0B4D47FC098Q34507092-7E26D22F-29C7-4E50-BDDB-0D0888F30CCFQ34631773-09A5D832-D016-4095-959E-0556E6226EB4Q34635596-4EC2CA2F-0489-48B6-B16B-27E8215EFBE7Q35023726-1964862D-9CB6-4A91-902C-6223B33306E7Q35798947-3CDF1AEB-0D93-4FA3-8353-B1E272844903Q36053380-B436F18B-3D95-47C9-9DF5-13635304A191Q36390277-9A4F842E-0332-45E7-AD57-1B373B47526AQ37087993-2D90ECD2-5F85-4BE8-A054-61ECA463E82AQ37310776-4E35496C-90FF-4BEE-91A4-F06C80E35A67Q37471073-F306ACF6-DA8D-4B99-B533-59E981FF8EC1Q37492042-DC1A6359-CF2D-44A1-B6F4-DB844ECA2A56Q37663461-0B94A6FE-E8E7-49D9-89E7-8E1F061D559CQ37699723-60C7EE61-6D6E-4A53-B4A8-F5A79E90FBF9Q37892536-CE950F6D-6AEC-4FCF-B378-4C0FEBDCD433Q38088116-25CB96AB-A9CF-4983-8300-6992C92A28CEQ38482259-363FA887-52AF-40EF-B380-8C23C8A65E00Q38688708-5CA42CDC-9D3D-44CE-B89E-9B1E111377B1Q38726747-51C09194-8BF5-4A68-9796-B7899439B894Q38728677-AFA16E28-94DB-4EF4-8A13-6B3C7145784BQ38763583-BBB40B2B-6D6D-43F2-9508-FF2EA4D90748Q38874120-026FAA97-71C7-4D01-B59B-8F162376D620
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Gerd Mikus
@ast
Gerd Mikus
@en
Gerd Mikus
@es
Gerd Mikus
@nl
Gerd Mikus
@sl
type
label
Gerd Mikus
@ast
Gerd Mikus
@en
Gerd Mikus
@es
Gerd Mikus
@nl
Gerd Mikus
@sl
prefLabel
Gerd Mikus
@ast
Gerd Mikus
@en
Gerd Mikus
@es
Gerd Mikus
@nl
Gerd Mikus
@sl
P214
P1053
D-4152-2013
P106
P1153
7003491525
P21
P214
P31
P3829
P496
0000-0003-1783-133X
P7859
viaf-64616559